Hodgkin Lymphoma

Recent advancements have significantly transformed the treatment landscape for relapsed or refractory classic Hodgkin lymphoma. The emergence of innovative therapies promises better outcomes and sets the path for personalized treatment strategies. Classic Hodgkin lymphoma cure rates have improved with chemotherapy, yet 10–30% of patients experience relapse or refractory disease. The last decade has witnessed the...

A comprehensive analysis of four clinical trials found that anti-programmed cell death-1 therapies may have long-term survival benefits in patients with relapsed or refractory classical Hodgkin lymphoma. However, results varied based on disease status and depth of remission, which may indicate a need for targeted treatment strategies. Anti-programmed cell death-1 therapies can prolong survival in...

A recent study found that rural residence and certain tumor types, such as Hodgkin lymphoma, are among the leading causes of delayed cancer diagnosis in children. Delayed cancer diagnosis in children is a significant global health problem. Moreover, in its early stages, cancer symptoms are non-specific. This risk of delayed diagnosis is exceptionally high in...

A new study shows that higher exposure to pesticides among rural workers puts them at risk of Hodgkin lymphoma, autoimmune disorders, and other health issues caused by genotoxicity. Though the Green Revolution has helped increase food production globally, it has resulted in the indiscriminate use of pesticides in some nations, putting rural populations at risk....

In a first-of-its kind study, researchers evaluated the association between Human Development Index data and the prevalence of Hodgkin lymphoma.  Hodgkin lymphoma (HL) has a global annual incidence of about 83,000, causing more than 23,000 deaths globally, per the online database GOBOCAN 2020. Approximately 95% of all cases of HL are of classical Hodgkin lymphoma...

With the development of more potent treatment options, the survival rate for Hodgkin lymphoma has increased over time. Treatment options for children with Hodgkin lymphoma (HL) have changed dramatically over the years, mainly as a result of developments in radiation therapy (RT) and chemotherapy (ChT). In the past, both children and adults received the same...

Pediatric patients with Hodgkin lymphoma should be treated according to risk- and response-adaptive care principles, according to a recent study. Hodgkin lymphoma (HL) is the most prevalent cancer in young adults, making up about 40% of all lymphomas in children. HL is also one of the most treatable cancers, with about an 80% cure rate...

Lymphoma is one of the most common and deadly cancers, ranking in the top 10 causes of cancer deaths. Despite its prevalence and severity, no blood test approaches to lymphoma screening have been implemented at the population level, and there are limited accurate surveillance markers. Methylated DNA markers (MDMs) have proven to be informative in...

Staff Writer: Deileta Kamhunga It’s well established that there are serious inequities in cancer care and outcomes in the U.S. and around the globe. But are pivotal clinical trials including populations representative of all patients, particularly those who experience these inequities? Researchers set out to determine if clinical trials for lymphomas reflect the populations affected...